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Abstract 
Purpose: To determine whether prophylactic inhaled heparin is effective for the prevention and 
treatment of pneumonia patients receiving mechanical ventilation (MV) in the intensive care 
unit. 
Methods: A phase 2, double blind randomized controlled trial stratified for study center and 
patient type (non-operative, post-operative) was conducted in three university-affiliated 
intensive care units. Patients aged ≥18 years and requiring invasive MV for more than 48 hours 
were randomised to usual care, nebulization of unfractionated sodium heparin (5000 units in 2 
mL) or placebo nebulization with 0.9% sodium chloride (2 mL) four times daily with the main 
outcome measures of  the development of ventilator associated pneumonia (VAP), ventilator 
associated complication (VAC) and sequential organ failure assessment scores in patients with 
pneumonia on admission or who developed VAP. Trial Registration: Australian and New Zealand 
Clinical Trials Registry ACTRN12612000038897. 
Results:  Two hundred and fourteen patients were enrolled (72 usual care, 71 inhaled sodium 
heparin, 71 inhaled sodium chloride).  There were no differences between treatment groups in 
terms of the development of VAP, using either Klompas criteria (6-7%, P=1.00) or clinical 
diagnosis (24-26%, P=0.85).  There was no difference in the clinical consistency (P=0.70), 
number (P=0.28) or the total volume of secretions per day (P=0.54). The presence of blood in 
secretions was significantly less in the usual care group (P=0.005).  
Conclusion: Nebulized heparin cannot be recommended for prophylaxis against VAP or to 
hasten recovery from pneumonia in patients receiving MV. 
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1. Introduction 
Unfractionated heparin (UFH) is an inexpensive naturally occurring sulphated 
glycosaminoglycan [1] which promotes mucociliary clearance [2], decreases sputum viscidity, [2] 
displays antibacterial effects on common respiratory pathogens, [3] and has anti-inflammatory 
properties. [4] Clinical applications have been reported in airway burns [5] and respiratory 
conditions where there is a significant sputum production or airway inflammation. [6] With these 
therapeutic effects, the potential role of UFH in preventing and treating lung infections including 
ventilator-associated pneumonia (VAP) remains insufficiently investigated. 
 
Nebulized administration to maximize drug concentrations in the epithelium of the airway may 
also enhance effectiveness. Indeed, UFH is simple and safe to administer by ventilator nebulizer 
with less than 1% of a 90,000 unit dose found in blood. [7] Doses of 30,000 units twice daily are 
not associated with significant changes in the coagulation profile. [8] Furthermore, recent work 
exploring the clinical role of nebulized UFH has demonstrated an 18% increase in ventilator free 
days in critically ill patients at risk of developing acute respiratory distress syndrome (ARDS). [9] 
 
With this strong theoretical background supporting the potential beneficial effects of nebulized 
UFH, we performed a feasibility Phase-2b double-blind, multicenter, randomized controlled trial 
in patients receiving mechanical ventilation (MV) to investigate the effectiveness of Inhaled 
Prophylactic Heparin In the preVention and treAtment of Pneumonia (IPHIVAP).  Primary study 
endpoints were the incidence, severity and time to develop VAP.  The incidence of ventilator 
associated complications (VAC), rate of resolution of pneumonia, and incidence and time to 
bacterial airway colonization were secondary endpoints.  
 
2. Materials and Methods: 
2.1 Study Population 
Patients aged ≥18 years who had received less than 24 hours of invasive MV at the time of 
enrolment and commencement of study drug but were likely to require invasive MV for more 
than 48 hours were eligible for study inclusion.  Patient exclusions included pregnancy, patients 
with treatment limitations or who were moribund, contraindications to subcutaneously 
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administered heparin, systemic anticoagulation at enrolment and previous enrolment in the 
study. Routine subcutaneous thromboembolism prophylaxis (≤ 15,000 units of unfractionated 
heparin per day or equivalent) and low dose heparin  to prevent clotting of continuous renal 
replacement therapies were permitted 
 
2.2 Randomization 
The study was coordinated from the Burns, Trauma and Critical Care Research Centre of the 
University of Queensland.  Secure randomization and data management were maintained by the 
Chinese University of Hong Kong.  Subjects were randomized to the 3 groups by concealed 
allocation.  A permuted block method stratified by study center and patient type (non-operative 
compared to post-operative) was employed.  The three groups included: (A) Intervention group - 
nebulized unfractionated sodium heparin (2 mL, 5000 units) every 6 hours, (B) Placebo group 1 - 
nebulized 0.9% sodium chloride 2 mL every 6 hours, (C) Placebo group 2 – no prophylactic 
nebulized treatment (usual care).  Apart from the “usual care” group, clinicians and data 
collectors remained blinded.  Treatment groups remained blinded during analysis.  
 
2.3 Study Drug Preparation and Administration 
Study drugs were prepared as sodium heparin 5000 units (1 mL) made up to 2 mL with sterile 
0.9% sodium chloride.  The placebo was 0.9% sodium chloride (2 mL).  Both were made using an 
aseptic technique by trained research staff not involved in clinical care of the patients, to ensure 
maintenance of blinding for all study and clinical staff.  
 
Participants received study drug until they ceased MV for more than 48 hrs, or were discharged 
from the ICU. If the patient required ventilation again for the same ICU admission, the study drug 
continued in the same treatment arm.  
 
2.4 Data Collection 
The study sample was defined by criteria including age, sex, Acute Physiologic And Chronic 
Health Evaluation (APACHE) II score [10], McCabe comorbidities [11], admission Sequential 
Organ Failure Assessment score (SOFA)[12], admission type, Intensive Care and hospital 
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mortality, lengths of stay and primary diagnoses in accordance with the Adult Patient Database 
of the Australian and New Zealand Intensive Care Society Centre for Outcome and Resource 
Evaluation(ANZICS-CORE). Chronic obstructive pulmonary disease (COPD) diagnosis used the 
criteria of the American Thoracic Society. [13] Antibiotic use and clinical indications were 
recorded. Community acquired pneumonia (CAP)[14], health care associated pneumonia 
(HCAP)[15], and aspiration pneumonia (AP) were determined by the treating clinicians at ICU 
discharge.  In addition, a Clinical Pulmonary Infection Score (CPIS)[16] was calculated at the time 
of diagnosis.  Patients were screened daily for the development of ARDS [17] and improvement 
monitored by the rate of change in daily PaO2/FiO2 ratios and chest X-ray scores.[18]  Smoking 
history was collected. Humidification technique and all additional nebulized therapies as deemed 
necessary by the treating clinician were recorded, however nebulized saline to treat thick 
secretions was not permitted.  Sequential Organ Failure Assessment (SOFA) scores were 
calculated at diagnosis and daily for all patients with pneumonia. Endotracheal secretions were 
recorded for each 24 hour period as the total number of suctions, and the volume of secretions as 
the daily sum of each suction: 0=nil, scant/small=1, moderate=2, large=3, copious=4. The number 
of suctions each hour with blood was tallied for each day. 
 
2.5 Clinical Interventions 
Interventions with known risks for VAP were standardized. [19]  Management of VAP followed a 
suggested therapeutic guideline. [20] Pneumonia treatment was determined by the treating 
clinician according to unit antibiograms, surveillance cultures or diagnostic culture results. The 
minimum duration of pneumonia treatment (including VAP) was 5 days.  For Pseudomonas 
aeruginosa, 7-days of therapy was provided consistent with the minimum duration of treatment 
recommended in Australia and New Zealand. [21] 
 
Semiquantitative bacterial surveillance cultures of endotracheal aspirates (ETA) using routine 
laboratory processing were performed on admission and then twice weekly. Patients with AP, 
CAP, HCAP or who developed VAP had additional ETA surveillance cultures for 10 days or until 
the patient no longer had an artificial airway. 
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Patients were screened daily using the validated modified Centre for Disease Control criteria for 
VAP of Klompas [22] with date of onset when all criteria were met.  The lead site assessed the 
effect of inhaled heparin on the development of VAC as defined by Klompas and the National 
Institutes of Health [23].  Only the first episode of VAC and VAP was included in the analysis.  
 
The definitions for clinical progress of pneumonia  (resolution, cure, or treatment failure) [24] 
and microbiological outcome (eradication, persistence, superinfection) [25] are summarized in 
the Supplementary Material (eTable 1).  
 
2.6 Safety Monitoring and Cessation Criteria 
Daily assessment as per usual unit protocol was made of peripheral platelet counts and 
coagulation profiles. Prolongation of the Activated Partial Thromboplastin Time (APTT) greater 
than 50%, or a fall of the platelet count <100 X 109/L suspended study drug delivery until clinical 
resolution in the absence of other clinical explanations. Thrombocytopenia < 100 X 109/L 
triggered screening for heparin induced thrombocytopenia syndrome (HITTS) if not previously 
investigated. Episodes of clinical bleeding were managed with suspension of the study drug with 
a local clinical decision made to recommence the study drug when bleeding had resolved. All 
adverse events and protocol violations were recorded. 
 
2.7 Sample Size, Data Management and Analysis Approach:  
Previous work by our group established the VAP rate in Australia to be 12% (range 4%-
21%).[26] IPHIVAP was powered to reduce the VAP rate from 12% to 6% using uncorrected chi 
square test for difference between proportions, an alpha of 0.05, power of 80% and a ratio of 2 
placebo groups to treatment. 277 patients were needed per group. Allowing for a 10% loss rate 
from the study, mainly from failure to complete a minimum of 48 hours of MV, 914 patients were 
required for the study. This proposed sample size encompassed the secondary hypothesis of a 
reduction in bacterial colonization. For a reduction of  bacterial colonization from 80 to 40%, the 
number per group needed was 35 using a Bonferroni correction for multiple comparisons, an 
alpha of 0.05 and a power of 80%.   
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A pragmatic decision was made to cease trial recruitment in December 2013 on the basis of both 
a revised sample size calculation (November 2013) and the observed recruitment rate between 
April 2011 and November 2013.  The primary endpoint using Klompas criteria for VAP was close 
to 6% in all study groups (November 2013). Therefore, to demonstrate a 1% difference between 
groups approximately 22,000 patients would be required, and as such the trial was ceased on the 
basis of futility. 
 
An intention-to-treat analysis was performed. Continuous data were analyzed using ANOVA and 
Kruskall-Wallis tests.  Categorical data were analyzed using Pearson’s chi-squared and Fisher’s 
exact tests as appropriate. Analysis included repeated measures mixed linear models with mean 
changes of scores, standard deviations and 95% confidence intervals (CI) calculated between 
groups. All tests of significance were two-tailed, and probability values less than 0.05 were 
considered significant. [27 28] Results were reported as means (range) and medians 
(interquartile range) and 95% CIs where appropriate.  Data were analyzed using STATA 12 
(College Station, Texas. United States) statistical software.  
 
2.9 Ethical Considerations: 
Institutional ethical consent was granted by each of the study sites.  The study conformed with 
the CONSORT guidelines for randomized controlled trials. [29] Informed consent was obtained 
for all participants. The trial was registered with the appropriate jurisdictions for Guardianship 
in all regions.  The trial was also registered with the Australian and New Zealand Intensive Care 
Society Clinical Trials Group (CTG 09-003) and the Australian and New Zealand Clinical Trials 
Registry (ACTRN12612000038897).   
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
   10 
3.0 Results 
The CONSORT diagram of patient enrolment is presented in Figure 1.  The demographics of all 
patients are summarized in Table 1. Study participants had a mean (range) age of 56 (18-86) 
years with a mean admission APACHE II score of 18.9 (0-46) and an admission SOFA score of 6 
(0-18). 141 (66%) were males and 90 patients (42%) had a diagnosis of pneumonia on ICU 
admission with the causative organisms detailed in Table 2.  Medical patients accounted for 64% 
with 45 (21%) having a history of COPD. The severity of McCabe comorbidities are detailed in the 
supplementary material (eTable 2). There were no significant differences in the characteristics of 
the study groups.  
 
Randomization was successful with approximately 33% of patients assigned to each study group. 
The failure to meet minimum ventilation times of 48 hours was similar in all groups (11-13%).  
Ventilation times were also similar with a median of 5.5 days (Table 3). Those receiving 0.9% 
Sodium chloride had higher use of antibiotics on admission (heparin 61%; 0.9% sodium chloride 
80%; usual care 67%, P=0.03) and developed ARDS more frequently during their ICU admission 
(heparin 14%; 0.9% sodium chloride 25%; usual care 8%, P=0.03). 
  
There was no difference in the development of VAP whether diagnosed clinically (heparin  28%; 
0.9% Sodium chloride 24%; usual care 26%, P=0.85) or by Klompas criteria (heparin 7%; 0.9% 
Sodium chloride 6%; usual care 7%, P=1.00) .  Time to develop VAP (approximately 7 days, 
P=0.34) was not different between the groups (Table 4.). There were no significant differences in 
the organisms causing VAP. VAC rates were similar in all groups, heparin 38%; 0.9% Sodium 
chloride 28%; usual care 32 %, P=0.59), (Table 4).  
 
For patients with pneumonia on admission or who developed VAP, there were no differences 
between the groups in organ specific SOFA scores over the first 5 days from the onset of 
pneumonia (P=0.56-0.96, eTable 3 in Supplementary Material).  No differences were found when 
CAP, HAP or VAP were assessed separately. 
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Although there were some baseline differences in airway colonization with more Candida spp 
colonization in the 0.9% sodium chloride group (27% compared to 11-15%, P=0.05) and 
Staphylococcus aureus in the heparin group (23% compared to 6-11%, P=0.01, eTable 4 in 
Supplementary Material), there were no differences in subsequent airway colonization after 
initiating mechanical ventilation (eTable 5 in Supplementary Material). 
 
The number of suctions per day (P=0.28) and the total volume of secretions per day (P=0.54) 
were similar for all groups but the presence of blood was significantly less in the usual care 
group (P=0.005, eTable 6 in Supplementary Material). 
 
There were no significant differences in adverse events between the groups (Table 4). There 
were similar prolongations of APTT and decrements in platelet counts.  Their associated timing 
with HITTS was suspected in 2 patients although not confirmed; one each in the heparin and 
saline groups. 
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4.0 Discussion 
 
In this general cohort of ICU patients, inhaled heparin did not have any significant effect on 
decreasing rates of VAP or VAC, time course for resolution of pneumonia, airway colonization or 
airway secretion volume. However, use of inhaled heparin was not associated with any 
significant adverse events.  
 
Published data of the possible effect of inhaled heparin for prevention and treatment of 
pneumonia in ICU supported further investigation.  In the current trial, doses of heparin used 
were consistent with previous studies in burns, [1] asthma, [30] bronchiectasis [31] and cystic 
fibrosis. [6] The lack of effect of heparin in this study compared to previous studies may have 
been due to different patterns of airway inflammation seen in acutely ventilated patients or a low 
baseline VAP rate.   
 
We did not see a reduction in days of MV compared with studies using much higher doses of 
heparin and a more sophisticated nebulization regimen. [9] However, the latter trial investigated 
a defined group of patients who had a high predilection score for ARDS, perhaps reflecting a 
more defined patient group who may benefit from inhaled heparin.  A similar example would be 
post cardiac surgical patients, where the extracorporeal circuit has been associated with 
intrapulmonary clots. [32] These patient groups were not included in the current trial.  
 
It was unlikely that inhaled heparin would have a systemic effect on inflammatory processes or 
coagulation.  Indeed, no differences were seen between the groups on coagulation tests or 
platelet counts consistent with other studies using similar doses of inhaled heparin. [33-35] The 
lack of any anti-inflammatory effect of inhaled heparin with severe pneumonia has been seen in 
animal models. [36] 
 
We did find that ARDS was more common in the nebulized 0.9% sodium chloride group but this 
group also had a higher prevalence of infections on admission to the ICU.  ARDS rates were 
however similar in the nebulized heparin and usual care groups. 
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Inhaled heparin has been shown to improve the rheological properties of sputum in airway 
inflammatory disease. [2]  However, given controlled airway humidification and the predominant 
use of hot water humidification in this trial, perhaps the effects of inhaled heparin or indeed 
inhaled sodium chloride are mitigated by adequate humidification. 
 
Although burns patients were included in the study, none had associated airway injury. Some 
studies recommend the use of inhaled heparin to resolve airway burns but definitive trials are 
yet to be published.  [5] 
 
This study had several limitations. Despite being small, there were no significant trends in the 
incidence of VAP or VAC, pneumonia resolution or effects on airway colonization or airway 
secretions to justify continued recruitment to the a priori sample size. This trial used robust 
definitions of VAP [22] and VAC [23] concordant with clinician determined “highly likely” VAP.  
The random permuted block design for randomization was successful despite the early cessation 
of the trial.  The ARDS definition was consistently applied although the study design predated 
currently accepted definitions. Two placebo groups were included in order to eliminate the 
potential confounding effect of nebulized saline on the outcomes of interest. [37]  It is possible 
that a higher dose is required  but a pragmatic decision was made to use dosages consistent with 
other airway inflammatory diseases where some benefit of inhaled heparin has been noted. [2], 
[3], [4], [5], [6] Importantly, the majority of patients were recruited from a single center.    
 
In summary, a dose of 5000 units of unfractionated heparin administered 4 times daily using 
commonly available nebulizers cannot be recommended for prophylaxis against nosocomial 
pneumonia or to improve recovery from pneumonia in patients receiving mechanical ventilation. 
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Figure 1. CONSORT Diagram of Patient Randomization 
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Table 1. Demographics of Study Patients 
Variable Heparin 
 
Median/N 
(%/IQR) 
0.9% Sodium 
chloride 
Median/N 
(%/IQR) 
Usual Care 
 
Median/N 
(%/IQR) 
Total 
 
Median/N 
(%/IQR) 
P 
N 71(33.1) 71 (33.1) 72 (33.2) 214 (100) 1.00 
Age*  57 
(35-69) 
59 
(41-69) 
62 
(49-71) 
59 
(42-70) 
0.29 
Male 45 (63) 49 (69) 47 (65) 141 (66) 0.77 
Patient Type             Non-
Operative 
Operative 
52 (73) 
19 (27) 
53 (75) 
18 (25) 
53 (74) 
19 (26) 
158 (74) 
56 (26) 
0.98 
Admission Pneumonia# 
Community Acquired 
Health Care Associated 
Aspiration 
All 
 
8 (11) 
7 (10) 
10 (14) 
25 (35) 
 
18 (25) 
9 (13) 
13 (18) 
40 (56) 
 
17 (24) 
3 (4) 
5 (7) 
25 (35) 
 
43 (20) 
19 (9) 
28 (13) 
90 (42) 
 
0.07 
0.15 
0.10 
0.02 
Clinical Pulmonary Infection 
Score 
8.2 (4-12) 7.4 (3-12) 6.6 (2-10) 7.4 (2-12) 0.09 
APACHE II# 18.8 (0-
46) 
18.2 (3-38) 19.6 (0-
44) 
18.9 (0-46) 0.63 
Sequential Organ Failure 
Assessment 
6.3 (0-18) 5.4 (0-17) 6.1 (0-19) 6 (0-18) 0.65 
Admission Type 
Medical 
Surgical 
Trauma 
 
41 (58) 
20 (28) 
10 (14) 
 
47 (66) 
29 (27) 
5 (7) 
 
48 (67) 
20 (28) 
4 (6) 
 
136 (64) 
59 (28) 
19 (9) 
0.46 
McCabe Co-morbidities       
Non-metastatic cancer 2 (3) 1 (1) 7 (10) 10 (6) 0.13 
Metastatic Cancer 4 (4) 1 (1) 1(1) 5 (2) 0.48 
Hematological Malignancy 1 (1.4) 1 (1.4) 3 (4) 5 (2) 1.00 
Bone marrow transplant 0 (0) 1 (1.4) 4 (6) 5 (2) 0.07 
Immunocompromised 2 (3) 4  (6) 8 (11) 14 (6.5) 0.32 
Chronic Renal Failure 3 (4) 5 (7) 8 (11) 16 (7.2) 0.59 
COAD 9 (13) 15 (21) 21 (29) 45 (26) 0.17 
Chronic Heart Failure 5 (7) 8 (11) 10 (14) 23 (11) 0.16 
Cirrhosis 2 (3) 2 (3) 3 (4) 7 (3) 0.90 
Diabetes mellitus 8 (11) 8 (11) 9 (12) 25 (12) 0.95 
Chronic Respiratory Failure 5 (7) 1 (1) 7 (10) 13 (6) 0.28 
Alcoholism 5 (7) 8 (11) 10 (14) 23 (11) 1.00 
Homelessness 1 (1) 3 (4) 3 (4) 6 (3) 0.46 
Drug Abuse 6 (8) 2 (3) 5 (7) 13 (7) 0.14 
Acquired Immune Deficiency 
Syndrome 
0 (0) 1 (1) 3 (4) 4 (3) 0.50 
Smoking 
Non-smoker 
Ceased < 3 months 
Ceased ≥ 3 months 
Presently Smoking 
Not Known 
 
8 (12) 
2 (3) 
8 (12) 
24 (35) 
26 (38) 
 
10 (15) 
2 (3) 
12 (18) 
27 (40) 
16 (24) 
 
9 (13) 
2 (3) 
16 (23) 
31 (44) 
13 (18) 
 
27 (13) 
6 (3) 
36 (17) 
82 (40) 
55 (27) 
0.36 
Hospital Outcome 
Death 
Discharge 
Transfer 
 
10 (14) 
56 (79) 
5 (7) 
 
13 (18) 
53 (75) 
5 (7) 
 
13 (18) 
53 (75) 
5 (7) 
 
11 (16) 
55 (80) 
3 (4) 
0.91 
ICU Outcome 
Death 
Discharge 
 
6 (8) 
60 (85) 
 
7 (10) 
59 (83) 
 
4 (6) 
64 (89) 
 
17 (8) 
183 (86) 
 
0.88 
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Transfer 5 (7) 5 (7) 4 (6) 14 (7) 
ICU Length of Stay* (Days)  6.8 
(4.0-13.3) 
8.2 
(4.0-12.0) 
6.8 
(3.6-13.6) 
7.3 
(3.9-13.0) 
0.81 
 
Hospital Length of Stay* 
(Days) 
 
21.3 
(10.4-
42.3) 
17.7 
(9.9-42.9) 
21.3 
(10-37.5) 
19.9 
(10.4-41.7) 
0.15 
 
* Median and IQR # Acute Physiologic and Chronic Health Evaluation (APACHE) 
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Table 2. Causative Organisms of Admission Pneumonia 
Organism N (%) 
Nil  
Gram Negative 
Staphylococcus aureus 
Viral 
Streptococcus pneumoniae 
Haemophilus influenzae 
Chlamydia spp. 
Legionella spp. 
Fungal 
Mycoplasma spp. 
Streptococcus pyogenes 
29 (34.5) 
19 (22.6) 
14 (16.6) 
7(8.3) 
5 (6) 
3 (3.6) 
2 (2.4) 
2 (2) 
2 (2) 
1 (1.2) 
1 (1.2) 
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Table 3. Treatment Events During Admission 
Variable Heparin 
 
 
N=71 
Median/N 
(%/IQR) 
0.9% 
Sodium 
chloride 
N=71 
Median/N 
(%/IQR) 
Usual Care 
 
 
N=72 
Median/N 
(%/IQR) 
Total 
 
 
N=214 
Median/N 
(%/IQR) 
P 
Tracheostomy 15 (21) 7 (10) 7 (10) 29 (14) 0.09 
Time to Tracheostomy (days) 
 
11.8 
(8.0-15.8) 
 
10.9 
(6.5-14.2) 
 
10.5 
(5.2-11.9) 
 
11.2 
(7.1-15.5) 
 
0.89 
Humidificationt 
HME 
HW 
Both 
 
1 (1) 
68 (96) 
2 (3) 
 
2 (3) 
68 (96) 
1 (1) 
 
1 (1) 
64 (89) 
7 (10) 
 
4 (2) 
200 (93) 
10 (5) 
0.15 
Antibiotics Day 1 ICU 43 (61) 57 (80) 48 (67) 148 (69) 0.03 
ARDStt 
Mild 
Moderate 
Severe 
 
0 (0) 
2 (3) 
11 (15) 
 
2 (3) 
0 (0) 
16 (23) 
 
0 (0) 
1 (1) 
6 (8) 
 
2 (1) 
3 (1) 
33 (15) 
0.04 
 
Dialysis Therapies* 
CRRT 
IHD 
Both 
 
10 (14) 
2 (3) 
1 (1) 
 
8 (11) 
1 (1) 
1 (1) 
 
12 (17) 
0 (0) 
2 (3) 
 
30 (14) 
3 (1) 
4 (2) 
0.81 
 
Method of Nebulization 
Jetttt 
Vibrating sieving meshttt  
Jet & Vibrating sieving meshttt 
None 
 
23 (32) 
16 (23) 
32 (45) 
0 (0) 
 
13  (18) 
24 (34) 
34 (48) 
0 (0) 
 
11 (15) 
12 (17) 
27 (38) 
22 (31) 
 
47 (22) 
52 (24) 
93 (44) 
22 (10) 
<0.0
01 
 
Additional Nebulizer Therapy 
Bronchodilators alone 
Bronchodilators &  
Corticosteroid 
Bronchodilators & Other 
Other# 
None 
 
23 (32) 
2 (3) 
 
1 (1) 
1 (1) 
44 (63) 
 
31 (44) 
2 (3) 
 
2 (3) 
0 (0) 
36 (51) 
 
37 (51) 
2 (3) 
 
2 (3) 
1 (1) 
30 (42) 
 
91 (43) 
6 (3) 
 
5 (2) 
2 (1) 
110 (51) 
0.38 
Duration of Mechanical 
Ventilation (days) 
5.5 
(2.4-11.0) 
5.7 
(2.2-9.7) 
5.1 
(2.2-10.0 
5.5 
(2.3-9.9) 
0.81 
Patients not reaching 2 days 
Mechanical Ventilation 
8 (11) 9 (13) 8 (11) 25 (12) 0.93 
Duration Antibiotic Use –all 
infection episodes (days) 
6 
(4-9) 
6 
(4-10.5) 
6 
(4-10) 
6 
(4-10) 
0.87 
Duration Antibiotic Use –
Admission CAP# (days) 
10 
(7-24) 
8.5 
(5-12) 
7 
(5-9) 
8 
(5-11) 
0.11 
Duration Antibiotic Use –
Admission HAP## (days) 
7 
(4-8) 
9 
(5-13) 
8 
(4-19) 
8 
(5-13) 
0.59 
Duration Antibiotic Use –
Admission AP### (days) 
3 
(2-4) 
7 
(4-11) 
7 
(4-10) 
5 
(3-10) 
0.17 
Duration Antibiotic Use –
Admission VAP$ by criterion 
(days) 
10 
(6-18) 
8.5 
(5.5-20.5) 
14 
(7-21) 
9 
(7-21) 
0.74 
Days antibiotics/Days LOS$$ 0.9 
(0.6-1.1) 
0.9 
(0.7-1.1) 
0.9 
(0.6-1.1) 
0.9 
(0.7-1.1) 
0.72 
t HME – heat and moisture exchanger (BB100, Pall Corporation, New York. USA) 
  HW - hot water (MR850AEA.  Fisher & Paykel Health Care. New Zealand) 
tt Acute Respiratory Distress Syndrome (ARDS) 
tttNebulizers: Jet-Hudson RCI jet nebulizer 
                         Vibrating sieving mesh-Aeroneb Pro/Pro X (Phillips. Amsterdam. Netherlands) 
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# Other nebulizations – lignocaine for cough/N-acetylcysteine 
* Continuous Renal Replacement Therapy (CRRT) Intermittent Hemodialysis (IHD) 
**median IQR# Other nebulizations – lignocaine for cough/mucomist 
* Continuous Renal Replacement Therapy (CRRT) Intermittent Hemodialysis (IHD) 
** Usual care patients were able to receive nebulized therapy as clinically directed but were not 
permitted to receive nebulized saline or heparin. 
# CAP-community acquired pneumonia 
## HAP-hospital acquired pneumonia 
### AP-aspiration pneumonia 
$ VAP-ventilator associated pneumonia 
$$ LOS-length of stay 
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Table 4. Ventilator Associated Pneumonia by Clinical Diagnosis and Klompas Criteria 
 
 Heparin 
 
N=71 
N/Median 
(%/IQR) 
0.9% Sodium  
chloride 
N=71 
N/Median 
(%/IQR) 
Usual Care 
 
N=72 
N/Median 
(%/IQR) 
Total 
 
N=214 
N/Median 
(%/IQR) 
P 
Clinically Diagnosed VAPt 
All 
High/Moderate 
High 
 
20 (28) 
12 (17) 
6 (8) 
 
17 (24) 
6 (8) 
5 (7) 
 
19 (26) 
7 (10) 
4 (6) 
 
56 (26) 
25 (12) 
15 (7) 
 
0.85 
0.27 
0.76 
VAP Klompas Criteria 5 (7) 4 (6) 5 (7) 14 (7) 1.00 
First episode of bacterial VAP  5 (7) 4 (6) 4 (6) 13 (6) 1.00 
Time to VAP-Klompas 
(Days)** 
7 (5-8) 7.5 (4-19) 8 (6-14) 7 (5-10) 0.35 
VAP Microorganisms 
Staphylococcus aureus 
Haemophilus influenza 
Stenotrophomonas 
maltophilia 
Serratia marcescens 
Enterobacter cloacae 
Klebsiella pneumoniae 
Proteus mirabulus 
Herpes simplex 
Streptococcus pneumoniae 
 
1 organism 
2 organisms 
 
Gram negative* 
Gram positive 
Both 
 
 
 
1 (20) 
1 (20) 
0   (0) 
 
1 (20) 
1 (20) 
1 (20) 
0   (0) 
0   (0) 
0   (0) 
 
5 (100) 
0 (0) 
 
4 (80) 
1 (20) 
0 (0) 
 
2 (50) 
1 (25) 
0   (0) 
 
0   (0) 
1   (25) 
0   (0) 
1 (25) 
0   (0) 
1 (25) 
 
1 (25) 
3 (75) 
 
1 (25) 
1 (25) 
2 (50) 
 
1 (20) 
1 (20) 
0   (0) 
  
0   (0) 
0   (0) 
1 (20) 
0   (0) 
1 (20) 
0   (0) 
 
3  (60) 
2 (40) 
 
3 (75) 
0 (0) 
1 (25) 
 
4 (29) 
3 (21) 
2 (14) 
 
1  (7) 
2 (14) 
2 (14) 
1  (1) 
1  (1) 
1  (1) 
 
9 (64) 
5 (36) 
 
8 (62) 
2 (15) 
3 (23) 
 
 
 
 
 
 
 
 
 
 
 
0.09 
 
 
0.42 
 
Ventilator Associated 
Complication 
Heparin 
N=68 
Saline 
N=67 
Usual Care 
N=67 
Total 
N=202 
P 
20 (29) 15 (22) 18 (23) 53 (25) 0.59 
t Ventilator Associated Pneumonia (VAP) 
* only bacterial isolates included ** median and IQR 
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Table 5.  Adverse Events 
Variable Heparin 
 
 
N=71 
Median/N 
(%/IQR) 
0.9%  
Sodium  
chloride 
N=71 
Median/N 
(%/IQR) 
Usual Care 
 
 
N=72 
Median/N 
(%/IQR) 
Total 
 
 
N=214 
Median/N 
(%/IQR) 
P 
Highest Activated 
Partial 
Thromboplastin 
Time* (sec) 
50 
(36-48) 
47 
(35-48) 
46 
(31-49) 
48 
(34-48) 
0.20 
Lowest Platelet Count 
(X 109/l) 
164  
(9-580) 
183  
(27-664) 
167  
(10-369) 
172  
(9-664) 
0.40 
Adverse Events 5 (7) 4 (6) 1 (1) 10 (5) 0.27 
Unrelated 4 (6) 4 (6) 1 (1) 9 (4) 0.34 
Possible related 1 (1) 0 (0) 0 (0) 0 (0) 1.00 
Definitely related 0 (0) 0 (0) 0 (0) 1 (0.5) 1.00 
Serious 1 (1) 0 (0) 1 (1) 2 (1) 1.00 
Confounding Factors 4 (6) 4(6) 1(1) 9 (4) 1.00 
Cessation Study Drug 
Permanent 
 
3 (4) 
 
2 (3) 
 
0 (0) 
 
5 (2) 
0.21 
Heparin. 
1. Discomfort experienced by patient during nebulization of study drug: rigors, choking 
sensation.  
2. Possible HITTS  
3. Rectal ulcer bleed requiring cessation of study drug 
4. Bleeding from intercostal catheter.  Settled with bronchoscopy 
5. Surgical Drain Bleeding-study drug had not commenced 
Saline 
1. Melena with fall of hemoglobin by 1 gram/dL 
2. Worsening coagulopathy and blood stained sputum 
3. Hemoptysis due to suction trauma. No fall in hemoglobin. SC heparin continued. 
Bleeding settled despite continuing study drug 
4. Bleed from surgical tracheotomy.  Though by treating team to be a surgical bleed. 
Normal coagulation profile but on aspirin and clopidogrel, 1 g/L HB loss 
Usual Care – usual care 
1. Significant thrombocytopenia 15x109/L from baseline of 60x109/L 
 
* median and interquartile range 
 
 
 
